InvestSMART

Nyrada Inc (ASX: NYR) - Share Price

Current share price for NYR : $0.520 0.02 (4%)+

Nyrada Inc (NYR) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a clinical-stage biotechnology company focused on the discovery and development of small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels.

NYR General Information +

ASX Code NYR
Website N/A
Industry/Sector Pharmaceuticals
Market Cap ($M) 134
NYR Share Price $0.520
Day High $0.520
Day Low $0.500
Last Close $0.500
NYR Share Price Movement $0.02 ( 4% )
Prices as at 16:40, 2 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Nyrada Inc (NYR) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Nyrada Inc (NYR) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Nyrada Inc (NYR) price-sensitive announcements

NYR - Xolatryp Demonstrates Cardioprotection in Preclinical Study
Nyrada Inc conducted a preclinical study to evaluate the efficacy of their drug Xolatryp i
Nyrada Inc (NYR)
21 Aug 2026 | 8:50 AM
NYR - Preliminary Final Report
Nyrada Inc.'s preliminary final report for the year ending 30 June 2026 shows a 14% declin
Nyrada Inc (NYR)
18 Aug 2026 | 1:05 PM
NYR - Quarterly Activities Report and Appendix 4C
Nyrada Inc, a clinical-stage biotechnology company, released its Quarterly Activities Repo
Nyrada Inc (NYR)
27 Jul 2026 | 8:44 AM
NYR - Response to ASX Price Query
Nyrada Inc., a biotechnology company focused on developing therapies targeting TRPC ion ch
Nyrada Inc (NYR)
15 Jul 2026 | 4:58 PM

Nyrada Inc (NYR) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Nyrada Inc (NYR)
CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED
Health Care $135 Nyrada US Patent for Xolatryp Granted 30 Sep 2026 4:22PM $0.500 $0.520 risen by 4%
Nyrada Inc (NYR)
CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED
Health Care $135 Cleansing Statement 25 Sep 2026 9:20AM $0.495 $0.520 risen by 5.05%
Nyrada Inc (NYR)
CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED
Health Care $135 Application for quotation of securities - NYR 25 Sep 2026 9:17AM $0.495 $0.520 risen by 5.05%
Nyrada Inc (NYR)
CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED
Health Care $135 Proposed issue of securities - NYR 21 Sep 2026 9:31AM $0.730 $0.520 fallen by 28.77%
Nyrada Inc (NYR)
CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED
Health Care $135 Proposed issue of securities - NYR 21 Sep 2026 9:31AM $0.730 $0.520 fallen by 28.77%
Nyrada Inc (NYR)
CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED
Health Care $135 Proposed issue of securities - NYR 21 Sep 2026 9:31AM $0.730 $0.520 fallen by 28.77%

NYR Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$6.56 -$2.70 13.20% 0.00 0.00 0.00% 0.0%
2025A -$4.85 -$2.40 184.70% 0.00 0.00 0.00% 0.0%
2024A -$1.39 -$0.90 -83.00% 0.00 0.00 0.00% 0.0%

NYR Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
Clarity Pharmaceuticals Ltd (CU6) $783M 0.4454 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $2,553M -0.7857 0.2462 0.9655 86.5492 69.4483 35.3333 0.00% 1.64% 1.94%
Nyrada Inc (NYR) $129M 0.1322 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

NYR Directors

Name Position Start Date
Mr James Bonnar Chief Executive Officer, Managing Director 8 Oct 2025
Dr Ian Edward Dixon Founder, Non-Executive Director 8 Sep 2020
Mr John Alexander Moore Non-Executive Chairman, Non-Executive Director 4 Jun 2019
Mr Ruediger Weseloh Non-Executive Director 4 Jun 2019
Mr Christopher Cox Non-Executive Director 7 Nov 2019
Mr Marcus Frampton Non-Executive Director 4 Jun 2019

Nyrada Inc (NYR) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
11 Jun 2026 BONNAR, James Buy Indirect Shares 4,400 $0.470 $2,068.000
11 Jun 2026 BONNAR, James Buy Indirect Shares 7,000 $0.460 $3,220.000
10 Jun 2026 BONNAR, James Buy Indirect Shares 6,000 $0.480 $2,880.000

See all changes in directors' interest & trades for Nyrada Inc (NYR) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

NYR Management

Name Position
David James Franks Company Secretary

NYR Calendar of Events

Date Event
17 August 2027 Report (Annual)
17 August 2027 Report (Prelim)
17 February 2027 Report (Interim)
10 November 2026 AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.